Analytics 4 Life® Rebrands as CorVista® Health; Appoints Scott Burger as Chief Commercial Officer and Vice President

TORONTO–(BUSINESS WIRE)–Analytics 4 Life today announced the appointment of Scott Burger to Chief Commercial Officer and Vice President. Scott will lead the commercialization efforts of the CorVista® System, a non-invasive point-of-care solution that allows physicians to rapidly assess heart function. The Company also announced it is rebranding to CorVista Health.

“Scott’s extensive operational leadership experience and unique expertise in software-based medical technologies in cardiovascular and pulmonary medicine will be critical as we advance the CorVista System,” said Don Crawford, Chief Executive Officer, CorVista Health. “I look forward to his leadership as we seek to improve care pathways for cardiac patients through earlier detection and timely diagnosis with non-invasive testing.”

Mr. Burger is an accomplished medical device professional with over 25 years of experience building and leading successful commercial teams. He has held executive sales positions with two software-based medical device startups where he led commercialization strategy, resulting in rapid growth and significant investment up-rounds totaling over $500M. Mr. Burger also served in key strategic leadership positions in Johnson & Johnson’s cardiovascular group. Mr. Burger received his B.S. in Chemistry from the University of North Dakota.

“Despite decades of research and progress, cardiovascular disease remains one of the leading causes of death in the United States and around the globe,” said Scott Burger, Chief Commercial Officer, Vice President, CorVista Health. “What’s more, the current public health crisis has significantly disrupted the healthcare system and the way we diagnose and treat patients. I look forward to being a part of a dedicated team focused on enabling better care for cardiac patients through the advancement of non-invasive solutions such as the CorVista System.”

In partnership with the CorVista Health commercial team, Scott led the rebranding of the company to reflect its evolution from an early-stage MedTech startup to a digital health company dedicated to improving cardiovascular disease diagnosis. CorVista Health embodies the company’s vision to transform the current standard-of-care for diagnosing cardiac conditions, reinforces a commitment to patients, and importantly enables future growth and expansion of the CorVista System.

About CorVista® Health

CorVista Health is applying machine learning to develop a novel cardiac diagnostic platform, CorVista® System, with the aim of transforming cardiovascular care and the patient experience. The CorVista System is a non-invasive, point-of-care solution that allows physicians to evaluate heart function without radiation, contrast agents, injections, fasting or exercise. For more information, visit www.corvista.com. The CorVista System is an investigational device limited by federal law to investigational use. The CorVista System is not available for commercial distribution.